JBC Focus on PI3-Kinase with Echelon

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Maroun, C. R.
Right arrow Articles by Park, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Maroun, C. R.
Right arrow Articles by Park, M.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

J Biol Chem, Vol. 274, Issue 44, 31719-31726, October 29, 1999


A Conserved Inositol Phospholipid Binding Site within the Pleckstrin Homology Domain of the Gab1 Docking Protein Is Required for Epithelial Morphogenesis*

Christiane R. MarounDagger , David K. Moscatello§, Monica A. NaujokasDagger , Marina Holgado-Madruga§, Albert J. Wong§, and Morag ParkDagger parallel **Dagger Dagger

From the Molecular Oncology Group, McGill University Hospital Center, Departments of Dagger  Medicine, parallel  Oncology, and ** Biochemistry, McGill University, Montréal, Québec, Canada H31 1A1 and the Departments of § Microbiology and Immunology and  Pharmacology, Kimmel Cancer Institute, Philadelphia, Pennsylvania 19107

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Stimulation of the hepatocyte growth factor receptor tyrosine kinase, Met, induces the inherent morphogenic program of epithelial cells. The multisubstrate binding protein Gab1 (Grb2-associated binder-1) is the major phosphorylated protein in epithelial cells following activation of Met. Gab1 contains a pleckstrin homology domain and multiple tyrosine residues that act to couple Met with multiple signaling proteins. Met receptor mutants that are impaired in their association with Gab1 fail to induce a morphogenic program in epithelial cells, which is rescued by overexpression of Gab1. The Gab1 pleckstrin homology domain binds to phosphatidylinositol 3,4,5-trisphosphate and contains conserved residues, shown from studies of other pleckstrin homology domains to be crucial for phospholipid binding. Mutation of conserved phospholipid binding residues tryptophan 26 and arginine 29, generates Gab1 proteins with decreased phosphatidylinositol 3,4,5-trisphosphate binding, decreased localization at sites of cell-cell contact, and reduced ability to rescue Met-dependent morphogenesis. We conclude that the ability of the Gab1 pleckstrin homology domain to bind phosphatidylinositol 3,4,5-trisphosphate is critical for subcellular localization of Gab1 and for efficient morphogenesis downstream from the Met receptor.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

The receptor for hepatocyte growth factor (HGF)1/scatter factor, Met, belongs to the family of receptor tyrosine kinases including Sea and Ron (1, 2). Met is expressed on epithelial and endothelial cells as well as on muscle precursor cells and neuronal cells and mediates the numerous biological responses attributed to the mesenchymally derived HGF (3-6). Increasing evidence demonstrates an important in vivo role for Met and HGF during the development of liver and placenta, as well as the development and innervation of skeletal muscle, the ductal growth of mouse mammary explants, and directing the growth of axonal cones (7-11). In culture, HGF is a potent mitogen for primary hepatocytes and renal tubule cells and stimulates epithelial cell dissociation, motility, and invasion (5, 12-14). Importantly, HGF triggers an intrinsic morphogenic program in epithelial cells grown in collagen matrices (15, 16). However, until recently the molecular basis underlying the morphogenic response of epithelial cells has remained unclear.

To characterize signaling pathways downstream from the Met receptor involved in epithelial morphogenesis, we and others have used receptor chimeras to demonstrate that the Met receptor cytoplasmic domain is sufficient for the biological responses attributed to HGF and that the Met tyrosine kinase activity is required for these responses (4-6, 17). From structure/function studies, two tyrosine residues within the carboxyl terminus of Met (Tyr1349 and Tyr1356), which are highly conserved between the other members of the Met receptor tyrosine kinase gene family, Sea and Ron, are crucial for cell scatter and branching morphogenesis in Madin-Darby canine kidney (MDCK) epithelial cells (2, 4, 5, 17). Tyrosine 1356 forms a multisubstrate binding site that couples the Met receptor directly with the Grb2 and Shc adapter proteins and is required for recruitment or phosphorylation of the p85 subunit of phosphatidylinositol 3-kinase (PI3K), phospholipase Cgamma 1 (PLCgamma 1), the phosphatase SHP2, the c-Cbl proto-oncogene, and the Gab1 (Grb2-associated binder-1) multisubstrate binding protein (17-24).

From a search for Met substrates that are implicated in epithelial morphogenesis, we have recently identified Gab1 as a protein that becomes highly phosphorylated following HGF stimulation of epithelial cells that undergo a morphogenic program (23, 24). Gab1 was initially identified in a library screen as a Grb2-binding protein that is phosphorylated downstream from multiple receptor tyrosine kinases including epidermal growth factor, insulin, and TrkA receptors and, more recently, members of the cytokine receptor family, interleukin-3, interleukin-6, interferon-alpha and -gamma receptors, and the erythropoietin receptor (25-28). Gab1 is a member of the IRS-1 family of multisubstrate binding proteins, including IRS-1, IRS-2, p62dok, and daughter of sevenless (29-33), and defines a new subfamily that includes a related protein, Gab2 (34). The greatest homology observed with the other IRS-1 family members lies within the N terminus of Gab1, which contains a pleckstrin homology (PH) domain, suggesting a conserved role for the PH domain within these proteins (25, 35). However, unlike IRS-1, Gab1 lacks a PTB domain and instead has been shown in vivo to be recruited to the Met receptor both indirectly, through the Grb2 adapter protein, and directly, involving the multisubstrate binding site tyrosines, Tyr1349 and Tyr1356, in the Met C terminus (20, 23, 36, 37). Gab1 contains multiple tyrosine residues, and following HGF stimulation of epithelial cells, it couples the Met receptor with the p85 subunit of PI3K and associated PI3K activity, SHP2, and PLCgamma 1 (24).

MDCK cells expressing Met receptor mutants with decreased ability to recruit Gab1 fail to form branching tubules upon Met activation (21, 23). Overexpression of Gab1 rescues the tubulogenesis defect of these mutants (24). To investigate the mechanism through which Gab1 mediates this function, we have undertaken a structure/function analysis of Gab1 and demonstrated that the Gab1 PH domain is essential for the ability of Gab1 to promote branching morphogenesis (24). In addition, we have established that the Gab1 PH domain is required to target Gab1 to the proximity of the cellular membrane, at sites of cell-cell contact in epithelial cells, and that this localization is also dependent on the activity of PI3K (24).

Increasing evidence supports a role for PH domains in the regulated targeting of proteins to cell membranes through their interactions with inositol phospholipids (reviewed in Refs. 38-40). Amino acid residues implicated in phospholipid binding are highly conserved among PH domains, including that of Gab1, suggesting that the Gab1 PH domain also interacts with membrane phospholipids (41, 42). This possibility is further supported by the recent findings that the Gab1 PH domain can bind to PIP3 in vitro2 and in a modified yeast two-hybrid system (41). To establish whether phospholipid binding by the Gab1 PH domain is a prerequisite for its function, we have mutated conserved amino acids in its beta 2 strand (Trp26 and Arg29) implicated in phospholipid binding from studies of Bruton's tyrosine kinase (BTK) and other PH domain-containing proteins (41-45). We show here that a similar mutation at residues Trp26/Arg29 in the PH domain of Gab1 generates Gab1 proteins with reduced binding to phosphatidylinositol 3,4,5-trisphosphate (PIP3) in vitro, reduced cellular localization to sites of cell-cell contact, and decreased ability to rescue Met-dependent morphogenesis.

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Cell Culture and DNA Transfections-- MDCK cells were maintained in Dulbecco's modified Eagle's medium (DMEM) containing 10% fetal bovine serum (FBS). The generation of MDCK cell lines expressing CSF-Met receptor and its mutant N1358H, by retroviral infection, has been previously described (6, 21). For the generation of stable cell lines expressing wild type and mutant HA-tagged Gab1, the Gab1 cDNA cloned into the pCDNA1.1 vector was cotransfected with a PLXSH vector, which confers resistance to hygromycin, by the calcium phosphate method as described elsewhere (24, 46). Cell lines were selected in hygromycin (300 µg/ml). For transient transfection assays, 293T cells were seeded at 1 × 106/100-mm Petri dish and transfected 24 h later with 2 µg of plasmid DNA encoding for wild type Gab1 or Gab1 mutants with or without CSF-Met or CSF-Met N1358H mutant cDNA following the calcium phosphate precipitation method (46). Sixteen hours later, cells were washed twice in DMEM lacking FBS and then cultured for another 48 h in media containing 10% FBS, following which the cells were harvested.

Antibodies-- Antibodies raised in rabbit against a C-terminal peptide of human Met were used (47). Anti-phosphotyrosine (4G10) was obtained from Upstate Biotechnology, Inc. (Lake Placid, NY). Anti-HA (HA.11) was purchased from Babco (Richmond, CA). Anti-SHP2 was kindly provided by Dr. G-S. Feng.

Site-directed Mutagenesis-- Site-directed mutagenesis within the Gab1 PH domain was performed using the ChameleonTM double-stranded site-directed mutagenesis kit (Stratagene), according to the manufacturer's instructions. Trp26/Arg29 residues were converted to either Cys or Ala residues. The mutagenesis primers were the following: for the C/C mutant, 5'-TCGCCCCCGGAGAAGAAGCTTAAGCGTTATGCGTGTAAGAGATGTTGGTTTGTGTTGCGCAGTGGC-3'; for the A/A mutant, 5'-TCGCCCCCGGAGAAGAAGCTTAAGCGTTATGCGGCGAAGAGAGCGTGGTTTGTGTTGCGCAGTGGC-3'. The underlined sequences are mutated.

Phospholipid Binding Assay-- GST fusion proteins were generated by cloning wild type Gab1 and A/A and C/C Gab1 mutants as a BamHI-EcoRI fragment into pGEX-5X-2 (Amersham Pharmacia Biotech) and expression in Escherichia coli BL21 strain. GST fusion proteins were purified on glutathione-Sepharose according to the manufacturer's instructions. GST fusion proteins (10 pmol) were bound to 30 µl of glutathione-Sepharose beads (Amersham Pharmacia Biotech) in 30 mM HEPES, pH 7, 100 mM NaCl, 1 mM EDTA, 0.025% Nonidet P-40 (HNE). Labeled phospholipids were sonicated in the same buffer containing 20 µg/ml Ser(P). Unlabeled competitor lipids (dipalmitoyl phosphatidylinositol 3,4-bisphosphate or phosphatidylinositol 3,4,5-trisphosphate; Matreya, Inc.) were sonicated at 100 µM with Ser(P) and 25 µM phosphatidylinositol 3,4-bisphosphate and diluted with Ser(P)/HNE, and constant amounts of labeled 32P-PIP3 (800,000 cpm) were added. Beads with bound fusion proteins were incubated with 40 µl of labeled phospholipid with or without competitor for 1 h at 22 °C, and the beads were quickly washed twice with 1 ml of HNE, 0.1% Nonidet P-40. Beads were subjected to extraction with 60 µl of CHCl3/CH3OH (1:1) and added directly to scintillation fluid for quantitation. Data presented were corrected for nonspecific binding by subtracting the counts bound to GST.

Immunofluorescence-- MDCK cells overexpressing wild type Gab1 or the Gab1 mutants were plated on glass coverslips (Bellco Glass Inc.) in a 24-well dish (Nunc) for the indicated times in DMEM containing 10% FBS. Cells were fixed in 2% paraformaldehyde in PBS for 30 min at room temperature, washed twice in PBS, and incubated for 10 min in PBS containing 50 mM ammonium chloride. Following one additional wash in PBS, cells were treated with PBS containing 0.1% Triton X-100 and 5% FBS (buffer A) for 10 min at room temperature. Anti-HA was diluted (1:300) in buffer A, and after three washes in the same buffer, CY3-conjugated anti-mouse (1:2000) was added for 10 min, followed by three washes in buffer A. The glass coverslips were mounted onto slides in Immunofluore medium (ICN) and visualized using a Nikon Labophot-2 epifluorescence microscope. Photographs were taken using Eastman Kodak Co. TMZ3200 film.

HGF Stimulation of MDCK Cell Lines Expressing Wild Type and Mutant Gab1-- Cells were seeded at 1 × 106/100-mm dish. Twenty-four hours later, cells were washed once with DMEM and then starved overnight in 10 ml of DMEM containing 0.02% FBS. HGF (kindly provided by Dr. G. F. Vande Woude) was added at 100 units/ml in 2 ml for the indicated times. Cells were immediately lysed in 1 ml of lysis buffer (50 mM Hepes, pH 7.4, 150 mM NaCl, 10% glycerol, 0.1% Triton X-100, 1 mM phenylmethylsulfonyl fluoride, 1 µg/ml each leupeptin and aprotinin, 1 mM Na3VO4).

Immunoprecipitations and Western Blotting-- MDCK cell lysates (2 mg of total protein), or 293T cell lysates (50 µg) were incubated with the indicated antibodies for 1 h at 4 °C with gentle rotation. Twenty microliters of a 50% slurry of either protein A- or protein G-Sepharose was added for an additional 1 h to collect immune complexes. Following three washes in lysis buffer, proteins were resolved by SDS-polyacrylamide gel electrophoresis and transferred to a nitrocellulose membrane. The membranes were blocked for 1 h with 3% bovine serum albumin in TBST (10 mM Tris-HCl, pH 7.4, 2.5 mM EDTA, 150 mM NaCl, 0.1% Tween 20) and then with primary antibody (1:1000) for an additional hour. Following five washes in TBST, proteins were revealed with secondary anti-mouse antibody (Jackson ImmunoResearch Laboratories, Inc.) or protein A (Life Technologies, Inc.) conjugated to horseradish peroxidase. The proteins were visualized with an ECL detection system (Amersham Pharmacia Biotech).

Collagen Assays-- The ability of MDCK cells to form branching tubules was assayed as described previously (17). Briefly, 5 × 103 cells were resuspended in 500 µl of collagen solution (Vitrogen 100 from Celtrix) prepared following the manufacturer's instructions and layered over 350 µl of the collagen solution in a 24-well plate. Cells were maintained in Liebowitz medium containing 5% FBS and allowed to form cysts for 5-7 days. For stimulations, HGF (5 units/ml) or recombinant human CSF-1 (50 ng/ml; kindly provided by Genetics Institute, Boston, MA) was added to the Liebowitz medium containing 5% FBS. Tubules were apparent by light microscopy 5-10 days after the addition of stimuli. The medium was changed every 4 days, and photographs were taken at day 14 on Kodak TMY400 films at a magnification of 10×. For the quantitation of the morphogenic response, 60 colonies in each of three independent cultures (wells) were scored for their ability to form branching tubules. The results were plotted as the average percentages derived from the number of cysts able to undergo tubulogenesis in cells expressing the Gab1 PH domain mutant proteins compared with cells expressing wild type Gab1.

    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Mutation of Conserved Residues in the Gab1 PH Domain Decreases the in Vitro Binding of Gab1 to Inositol 3,4,5-Trisphosphate-- We have previously demonstrated that Gab1 functions as a multisubstrate docking protein that mediates branching morphogenesis downstream from the Met receptor (23, 24). From structure/function analysis, we have established that the Gab1 PH domain is essential for the ability of this protein to promote morphogenesis and is both necessary and sufficient for the localization of Gab1 to sites of cell-cell contact (24). While cellular localization of Gab1 is also dependent on the activity of PI3K (24), the exact mechanism through which Gab1 localizes to sites of cell-cell contact has not been determined.

While PH domains are found in proteins with a broad range of activities, the three-dimensional structure of this motif is common to all; seven beta -strands form two anti-parallel beta -sheets that end with an alpha -helix (reviewed in Refs. 38 and 39). Insight into the role of this domain comes from the identification and characterization of inositol phospholipids as specific ligands for several PH domains (39, 42, 43, 45, 48-52). Thus, such protein-lipid interactions provide a mechanism through which PH domain-containing proteins can be recruited to membranes where they are required to function. In vitro binding studies of a number of isolated PH domains and use of a modified yeast two-hybrid system have allowed the grouping of PH domains based on their lipid binding specificity (41, 42, 53). From the crystal structure (51, 54) and the alignment of several PH domains within the various groups, a model involving a consensus amino acid sequence was generated, which includes a W(R/K)XR motif in the lipid binding domain (41, 42). Alignment of the Gab1 PH domain with other PH domains known to bind PI3K products indicates that the highly conserved Arg28 residue in the BTK PH domain, within the beta 2 strand, is also found in the PH domain of Gab1 (Arg29) (Fig. 1A). A less conserved residue, Trp26, is found in several but not all PH domains (Fig. 1A). To investigate the role of the Gab1 PH domain in epithelial morphogenesis and in Gab1 cellular localization, we have undertaken site-directed mutagenesis within the putative phospholipid binding site of the Gab1 PH domain and first studied the effect of such mutations on the ability of Gab1 to bind PIP3. The conserved Trp26/Arg29 residues were replaced either by alanine residues (A/A), rendering the charge at these sites neutral, or by cysteine residues (C/C), thereby mimicking the R28C mutation found in BTK of mice with X-linked immunodeficiency (51, 64-67).


View larger version (38K):
[in this window]
[in a new window]
  		Fig. 1.   Alignment of the PH domain of Gab1 with PH domains from other proteins known to bind PI3K products. A, PH domains from Gab1 (amino acids 7-35, GenBankTM accession number HSU43885 (25)), daughter of sevenless (amino acids 7-35, GenBankTM accession number X97447 (31)), BTK (amino acids 5-33, GenBankTM accession number L29788 (76)), and AKT (amino acids 7-31, GenBankTM accession number X65687 (77)) were aligned using the Mac Vector ClustalW formatted alignment program. The beta 1 and beta 2 strands are delineated by the arrows below the sequences. Conserved residues are highlighted in gray boxes. The Trp26 and Arg29 residues are marked by arrows above the sequences. B, schematic representation of Gab1 proteins used in this study. Shown is a wild type Gab1 protein in comparison with the A/A and the C/C mutant Gab1 proteins as well as the Gab1 mutant lacking the entire PH domain (Delta PH). The mutated residues are indicated by an asterisk above the corresponding residues in the wild type molecule.

To determine the phospholipid binding capacity of the Gab1 mutants, we have generated mutant GST-A/A and GST-C/C Gab1 bacterially produced fusion proteins and assayed the ability of these proteins to bind 32P-PIP3. As shown in Fig. 2, mutation of the Trp/Arg residues into either alanine or cysteine residues results in a 50% reduction in the ability of these mutated proteins to bind PIP3 as compared with GST-wild type Gab1. Further, we compared the ability of unlabeled PIP3 and PIP2 to compete with 32P-PIP3 binding and show that unlabeled PIP3 (100 µM) efficiently displaces 32P-PIP3, whereas a similarly high concentration (100 µM) of unlabeled PIP2 does not. These results not only indicate that the loss of the conserved residues in the Gab1 PH domains correlates with a reduction in phospholipid binding but also that the remaining PH domain-lipid interaction is preferentially directed to PIP3.


View larger version (30K):
[in this window]
[in a new window]
  		Fig. 2.   Reduced binding of A/A and C/C mutant Gab1 proteins to PIP3. PIP3 binding assays were performed as described under "Experimental Procedures." GST fusion proteins were immobilized on glutathione-Sepharose beads and incubated with 32P-PIP3 in the presence or absence of competitor phospholipids. Following washing, the bound phospholipids were extracted, and radioactivity was quantitated by liquid scintillation. The data were corrected for nonspecific binding by subtracting the counts bound to GST alone, and are the means ± S.D. of duplicate determinations. Open bars, no competitor; thin stripes, 100 µM PIP2; thick stripes, 10 µM PIP3; black bars, 100 µM PIP3.

The Conserved Phospholipid Binding Site within the Gab1 PH Domain Is Required for the Ability of Gab1 to Localize to Sites of Cell-Cell Contact-- PH domains have been shown to be essential for the localization of multiple proteins to the plasma membrane. For example, deletion of the PH domain from PLCdelta 1 or specific mutations that alter phospholipid binding within this domain resulted in the relocalization of this protein to the cytoplasm (55, 56). We have shown that the PH domain of Gab1 is necessary for the localization of Gab1 to the proximity of the cell membrane at sites of cell-cell contact in epithelial cells and that the PH domain of Gab1 alone is sufficient for membrane recruitment of Gab1 (24). Moreover, Gab1 localization at the plasma membrane is dependent on PI3K activity (24), suggesting that PI3K-generated phospholipids were directly or indirectly implicated in the recruitment of Gab1 to the plasma membrane.

It is widely accepted that the molecular basis through which PH domains are targeted to membranes involves binding to membrane phospholipids. The PH domain of Gab1 binds PIP32 (Fig. 2, and Ref. 41); therefore, to test the possibility that PIP3 targets Gab1 to the plasma membrane, we have generated stable cell lines expressing HA epitope-tagged A/A or C/C mutant Gab1 proteins with reduced PIP3 binding. The level of expression of the mutant proteins is analogous to that observed in cells expressing wild type Gab1, indicating that mutation of the phospholipid binding site within the Gab1 PH domain has no detectable effect on protein stability (Fig. 3A). To investigate the cellular localization of the mutant Gab1 proteins, MDCK cell lines expressing each mutant were grown on glass coverslips and subjected to indirect immunofluorescence using anti-HA (Fig. 3B). As previously demonstrated by fluorescence microscopy, the majority of wild type Gab1 is localized at the cell periphery and, more specifically, at sites of cell-cell contact in MDCK cells that grow in tight colonies. In contrast, both the A/A and the C/C Gab1 mutant proteins are predominantly localized in the cytoplasm (Fig. 3B), demonstrating that an intact Gab1 PH domain is required for the localization of the Gab1 protein at the cell periphery and, moreover, that a functional phospholipid binding site in the Gab1 PH domain is crucial.


View larger version (106K):
[in this window]
[in a new window]
  		Fig. 3.   A PIP3 binding site in the Gab1 PH domain is required for localization of Gab1 to sites of cell-cell contact. A, lysates from MDCK cells overexpressing wild type Gab1 or two representative clones expressing A/A or C/C mutant Gab1 proteins were subjected to immunoprecipitation with anti-HA, and proteins resolved by SDS-polyacrylamide gel electrophoresis were transferred to a nitrocellulose membrane and immunoblotted with anti-HA. B, MDCK cells (104 cells) stably expressing either wild type Gab1 (WT), Delta PH Gab1, A/A, or C/C were grown for 72 h on glass coverslips, in medium containing 10% FBS. Cells were fixed in 2% paraformaldehyde and labeled with anti-HA followed by CY3 conjugated anti-mouse. Photographs were taken at a magnification of × 60.

The Conserved Trp26/Arg29 Residues Are Not Required for Phosphorylation of Gab1 or Its Association with the Met Receptor-- Association of the Met receptor tyrosine kinase with Gab1 in coimmunoprecipitation assays is dependent on Tyr1349/Tyr1356 in the Met C terminus or on the presence of a Grb2 binding site downstream from Tyr1356 (23, 24, 36, 37). To determine whether the conserved Trp26/Arg29 residues in the Gab1 PH domain are required for the interaction Gab1 with the Met receptor, transient transfection assays in 293T cells were performed. The ability of wild type Gab1 and mutants thereof to coimmunoprecipitate with either wild type Met receptor or the Grb2 binding mutant (N1358H) was evaluated. Wild type Met coimmunoprecipitated with the A/A and C/C Gab1 mutant proteins as efficiently as with wild type Gab1. This is revealed using anti-Met for the immunoprecipitations followed by Western blotting using anti-HA or the converse (Fig. 4). The N1358H Met receptor mutant, as described previously, associates less efficiently with Gab1 when compared with wild type Met. However, both A/A and C/C Gab1 mutants are comparable with wild type Gab1 in their efficiency to coimmunoprecipitate with N1358H Met (Fig. 4). Stripping of the blots and reprobing with anti-HA shows that similar levels of Gab1 proteins are expressed in the different experimental groups (Fig. 4).


View larger version (33K):
[in this window]
[in a new window]
  		Fig. 4.   Coimmunoprecipitation of the Met receptor with WT, A/A, and C/C Gab1 proteins. Transient transfection assays were performed in 293T cells with vectors encoding for wild type CSF-Met or the N1358H CSF-Met mutant, together with either wild type Gab1 or A/A or C/C mutant Gab1 proteins. Lysates were generated 72 h after transfection and subjected to immunoprecipitation with anti-HA or anti-Met and immunoblotted with anti-HA or anti-Met as indicated.

We have previously demonstrated in MDCK epithelial cells that Gab1 becomes highly phosphorylated following Met receptor activation (23, 24). As a consequence, Gab1 associates with several signaling proteins including the phosphatase SHP2 and the p85 subunit of PI3K (24). Further, we have demonstrated that the kinetics of Gab1 phosphorylation is distinct following activation of the Met receptor or the epidermal growth factor receptor. In the former, HGF induces sustained Gab1 phosphorylation that lasts at least 60 min before returning to basal levels (24). Importantly, stimulation of Gab1-overexpressing MDCK cells with epidermal growth factor does not induce branching morphogenesis. In these cells, stimulation with epidermal growth factor results in transient phosphorylation of Gab1, which returns to base line within 15 min of stimulation (24), suggesting that the kinetics of Gab1 phosphorylation is implicated in Gab1 biological activities.

To investigate whether phospholipid binding of the Gab1 PH domain is implicated in Gab1 phosphorylation downstream from the Met receptor, stable MDCK epithelial cell lines expressing either HA epitope-tagged Gab1 A/A or C/C mutant proteins were stimulated with HGF. An increase in the level of phosphorylation of A/A and C/C Gab1 mutant proteins is observed within 15 min of stimulation, which is maintained for 60 min (Fig. 5). This increase is comparable both in intensity and duration with that observed in cells expressing wild type Gab1. Further, mutation of the Trp26/Arg29 conserved residues into either alanine or cysteine residues does not detectably alter the ability of these proteins to coimmunoprecipitate with SHP2 (Fig. 5) or p85 (not shown). Thus, mutations in the beta 2 strand of the PH domain that result in reduced phospholipid binding by Gab1 do not interfere with Met-dependent Gab1 phosphorylation or the binding of Gab1 to signaling proteins. These results are consistent with our previous findings that deletion of the entire PH domain had no effect on Gab1 recruitment to the Met receptor, Gab1 phosphorylation, or its ability to bind cellular signaling proteins.


View larger version (27K):
[in this window]
[in a new window]
  		Fig. 5.   The A/A and C/C mutant Gab1 proteins are phosphorylated following Met activation. MDCK cells expressing wild type Gab1 (clone 9, WT-9), A/A Gab1 (clone 2, A/A-2), and C/C Gab1 (clone 1, C/C-1) were serum-starved for 24 h prior to stimulation with 100 units/ml HGF for the indicated times. Gab1 proteins were immunoprecipitated with anti-HA and subjected to Western blotting with anti-PY (left panel). Membranes were stripped and reprobed with anti-SHP2 (middle panel). 50 µg of proteins from lysates of the different experimental groups were resolved on a 10% SDS-polyacrylamide gel, transferred to nitrocellulose, and blotted with anti-HA to ensure equivalent levels of proteins in all groups (right panel).

An Intact Gab1 PH Domain Is Required for Efficient Rescue of Branching Tubulogenesis Downstream from the Met Receptor-- Structure/function studies using chimeric CSF-Met receptor mutants have revealed that receptor mutants impaired in their association with Gab1 are unable to induce branching tubules (17, 21). Thus, cell lines expressing a CSF-Met receptor mutant that is specifically unable to bind Grb2 (N1358H) and shows reduced Gab1 recruitment fail to form branching tubules in response to CSF-1 (23, 24). Importantly, overexpression of Gab1 in these lines rescues the ability of CSF-Met to promote branching tubules in response to CSF-1. This response requires the Gab1 PH domain, since mutant Gab1 proteins lacking the entire PH domain fail to rescue (24). To establish if the Gab1 PH domain point mutants A/A or C/C, which retain the PH domain yet show reduced phospholipid binding and reduced localization at sites of cell-cell contact, are able to rescue branching tubulogenesis downstream from the N1358H CSF-Met receptor mutant, five independent cell lines overexpressing each mutant Gab1 protein were generated by transfection. The ability of these to form branching tubules following activation of CSF-Met N1358H mutant receptor with CSF-1 was assayed and compared with the ability of each cell line to form tubules following activation of the endogenous Met receptor by HGF. The level of expression of Gab1 in two representative cell lines is shown (Fig. 6A); the tubulogenic response is shown for one clone, and the quantitation of this response is shown for two clones (Fig. 6, B and C).


View larger version (40K):
[in this window]
[in a new window]
  		Fig. 6.   Trp26/Arg29 residues are required for efficient rescue of branching tubulogenesis downstream from the N1358H CSF-Met mutant receptor. A, lysates from MDCK cells expressing the CSF-Met N1358H mutant receptor and either wild type Gab1 or Gab1 mutants, as indicated in the figure, were subjected to immunoprecipitation with anti-HA followed by Western blotting using the same antibody. Two representative lines, each expressing A/A or C/C mutant Gab1 proteins, are shown. B, quantitation of the tubulogenic response following stimulation with HGF and CSF in cell lines expressing N1358H CSF-Met receptor with either wild type Gab1 or the Gab1 mutants was performed as described under "Experimental Procedures." The responses are plotted as the average percentage of cysts that have undergone branching tubulogenesis in the cells expressing mutant Gab1 compared with wild type Gab1-expressing cells. The values were derived from three independent experiments. C, MDCK cell lines expressing the CSF-Met N1358H mutant together either with wild type Gab1 (WT-3), the A/A Gab1 mutant (A/A-6), the C/C Gab1 mutant (C/C-7), or the Delta PH Gab1 mutant (Delta PH-3) were grown in collagen for 5 days, during which they formed cysts. Recombinant human CSF-1 (50 ng/ml) or HGF (5 units/ml) was added, and 14 days later branching tubules were visualized at a magnification of × 10. Photographs were taken with Kodak TMY 400 film.

As previously demonstrated, cells expressing the N1358H CSF-Met Grb2 mutant do not form branching tubules in response to CSF, and overexpression of a wild type Gab1 protein in these lines rescues the tubulogenic response, whereas cells expressing a Delta PH Gab1 mutant are unable to rescue (Fig. 6, B and C). Cells expressing the A/A and the C/C Gab1 mutants form cysts, as do parental cells when grown in a collagen matrix; however, they show reduced ability to form branching tubules when the chimeric CSF-Met N1358H protein is stimulated with CSF-1. Comparison of cell lines expressing the Gab1 PH domain A/A and C/C mutants with cell lines expressing wild type Gab1 reveals that 50% of preformed cysts from the A/A mutant-expressing cell lines undergo branching tubulogenesis (Fig. 6, B and C). Interestingly, the response of cells expressing the C/C mutant Gab1 protein is more severely altered. Only two of the five cell lines tested are able to form branching tubules, and quantitation of this response reveals that only 18 and 0.8% of cysts in these two cell lines are able to form branching tubules when compared with cells expressing wild type Gab1 (Fig. 6, B and C). Furthermore, the expression of the A/A and C/C Gab1 mutants per se does not interfere with the intrinsic ability of these cells to form branching tubules in response to HGF (Fig. 6, B and C). Thus, the reduced binding of A/A and C/C Gab1 mutants to PIP3 correlates with reduced ability of these proteins to rescue branching morphogenesis downstream from the CSF-Met N1358H receptor.

    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Hepatocyte growth factor and the Met receptor tyrosine kinase regulate dispersal of epithelial cell sheets in culture and promote the inherent morphogenic program of epithelia when grown in matrix cultures (5, 15, 16). We have recently demonstrated that the multisubstrate docking protein Gab1 is required for epithelial morphogenesis downstream from the Met receptor (24). Met receptor mutants that are unable to associate with Gab1 are impaired in their ability to promote branching tubulogenesis in MDCK cells, and overexpression of Gab1 rescues the Met-dependent tubulogenic response (21, 24). Structure/function analysis had revealed that the Gab1 PH domain is required for the rescue of tubulogenesis and for localization of Gab1 to the proximity of the cell membrane at sites of cell-cell contact (24). However, the mechanism through which the Gab1 PH domain provides its function in branching morphogenesis and cellular localization had remained unclear. In this paper, we show that conserved residues within the beta 2 strand of the PH domain, Trp26 and Arg29, are required for efficient binding of Gab1 to the PI3K product PIP3. Moreover, the ability of Gab1 to bind PIP3 is required for the localization of Gab1 at sites of cell-cell contact and rescue of Met-mediated branching tubulogenesis.

A large body of literature implicates PH domains in the targeting of proteins to cellular membranes, through interaction with inositol phospholipids (39, 45, 48, 49, 51, 52, 55-60). Recently, PH domains have been subdivided into four groups based on their inositol phospholipid binding specificity (41, 42, 53). PH domains in group I are those with the highest affinity for the PI3K product PIP3. Included in this group are PH domains from the protein tyrosine kinase BTK, as well as the IRS-1 family member daughter of sevenless and Grp-1. Group II members bind either PIP3 or PIP2 with a lower affinity of binding and include PLC-delta 1. Group III contains AKT/PKB, which binds preferentially to phosphatidylinositol 3,4-bisphosphate, although binding to PIP3 has also been reported (45, 48, 61, 62). PH domains from group IV bind weakly to inositol phospholipids as, for example, the PH domain from dynamin (41, 42, 53). Importantly, such studies have allowed the identification of a consensus sequence in PH domains that bind to PIP3, W(R/K)XR (Ref. 41, Fig. 1). However, while the phospholipid binding specificity has been determined for many proteins, the biological relevance for such lipid-protein interactions has been characterized predominantly for PH domain-containing proteins with enzymatic activities, BTK, AKT, PLCgamma 1, and PLCdelta 1, and not for members of the family of multisubstrate proteins like Gab1 (48, 63-69). This study is the first to define the biological relevance of lipid-protein interactions for the Gab family of multisubstrate proteins.

From a modified yeast two-hybrid screen and in vitro studies, the PH domain from Gab1 binds PIP3 and is placed with Group I2 (41). Moreover, the Gab1 PH domain contains the conserved W(K/R)XR motif that has been suggested both by crystallographic studies and by sequence comparisons to be conserved among proteins that bind products of PI3K (Fig. 1) (41, 54, 66, 70). Mutation of Arg28 in the BTK PH domain or Arg25 within the AKT/PKB PH domain results in a reduction in the ability to bind to PIP3 or phosphatidylinositol 3,4-bisphosphate, respectively (42-45). Similarly, substitution of the W/R motif in the Gab1 PH domain with either alanine (A/A) or cysteine (C/C) residues decreases its ability to bind PIP3 by 50%, in in vitro assays (Fig. 2). The residual PIP3 binding may suggest that a site(s) in Gab1, in addition to the W/R motif, is involved in inositol phospholipid binding. Additional lipid binding sites were shown following mutational analyses of PLCgamma 1 and BTK, where the variable loop between the beta 3 and beta 4 strands of the PLCgamma 1 PH domain and the beta 4 strand of the BTK PH domain was required for binding to inositol phospholipids (66, 71). Thus, it remains to be determined if sites outside of the beta 2 strand are also implicated in binding of the Gab1 PH domain to inositol phospholipids.

Gab1 proteins with mutations of the conserved inositol phospholipid binding site, W/R, fail to localize at sites of cell-cell contact and instead appear predominantly localized to the cytoplasm (Fig. 6). This is in agreement with our previous observations that the localization of Gab1 at sites of cell-cell contact was dependent the presence of the Gab1 PH domain and on PI3K activity, suggesting that PI3K-generated phospholipids were required (24). Hence, we conclude that the generation of PIP3 downstream from PI3K provides binding sites for the Gab1 PH domain and acts to recruit Gab1 to the plasma membrane at sites of cell-cell contact. Moreover, mutation of the W/R motif in Gab1 reduces the ability of Gab1 to rescue branching morphogenesis to 50% (A/A) and <18% (C/C), indicating that the integrity of the conserved phospholipid binding site is critical for Gab1 biological activities and membrane localization. The ability of either mutant Gab1 protein to partially rescue branching tubulogenesis may reflect the fact that both mutant proteins retain the ability to bind PIP3 in vitro, although at reduced levels (Fig. 2), whereas a Gab1 protein lacking the PH domain fails to bind detectable levels of PIP3 in vitro2 and is unable to rescue tubulogenesis (24). Hence, these studies together with the interaction of Gab1 with PIP3 both in vitro2 (Fig. 2) and in a modified yeast two-hybrid system (41) provide strong evidence that PIP3 is a physiological ligand for the Gab1 PH domain.

While the integrity of the PH domain is critical for efficient rescue of tubulogenesis by Gab1, we show that this is not related to alterations in the ability of the mutant Gab1 proteins to be recruited to the Met receptor or to their tyrosine phosphorylation following stimulation of cell lines with HGF (Figs. 4 and 5). Moreover, following stimulation of cells with HGF, the W/R mutant Gab1 proteins associate with SHP2 and the p85 subunit of PI3K to similar levels as wild type Gab1, indicating that the association of Gab1 with known substrates is not altered. However, we do observe that the electrophoretic mobility of phosphorylated W/R mutant Gab1 proteins is slightly faster than that of wild type Gab1 proteins (Fig. 4), although no detectable changes in the electrophoretic mobility of the unphosphorylated mutant proteins are observed (Figs. 3A and 6A). Thus, these mutations may result in decreased and/or altered phosphorylation of Gab1 (Fig. 4). These results are consistent with our previous data showing that the Gab1 PH domain is dispensable for Gab1 phosphorylation and association with Met and suggest a distinct role for the Gab1 PH domain in signaling downstream from the Met receptor. These data support two mechanisms for recruitment of Gab1 to the membrane. One involves the interaction of the Gab1 PH domain with PIP3 and is required for localization of Gab1 at cell-cell junctions in epithelial cells. However, Gab1 lacking its entire PH domain or mutated in the W/R motif in its PH domain can still be recruited to the Met receptor at the cell membrane (Ref. 24, Fig. 4).

In conclusion, Gab1 functions as a multisubstrate docking protein that is required for epithelial morphogenesis downstream from the Met receptor (24). Structure/function analyses have revealed that the Gab1 PH domain is required for the localization of Gab1 at sites of cell-cell contact and its biological activities. Here, we have presented molecular and biochemical evidence that PIP3 is a physiological ligand for the Gab1 PH domain required for subcellular localization of Gab1 to sites of cell-cell contact and biological activities of Gab1. We propose that the recruitment of Gab1 and its associated signaling proteins to membrane domains rich in PIP3 and/or its stabilization at those sites is crucial for Gab1 to amplify/compartmentalize signals generated downstream from the Met receptor. Recently, both amplification of PI3K and loss of function of a 3' lipid phosphatase, PTEN/MMAC1, have been shown in multiple human tumors (72-75), demonstrating that the regulation of PIP3 at the cellular membrane may be critical for the control of multiple biological processes including tumorigenesis. Thus, understanding the molecular mechanisms through which Gab1 subcellular localization and function are regulated during epithelial morphogenesis will provide insight into how the epithelial organization may be altered during the progression of cancers.

    ACKNOWLEDGEMENTS

We are grateful to Dr. G. F. Vande Woude for HGF and Genetics Institute for recombinant CSF-1, Dr. G. S. Feng for anti-SHP2, and members of the Park laboratory for helpful comments.

    FOOTNOTES

* This work was supported by an operating grant from the National Cancer Institute of Canada with funds from the Canadian Cancer Society (to M. P.), an American Cancer Society Grant, and National Institutes of Health Grants NS 34514 and CA69495 (to A. J. W.), with financial support from the Medical Research Council as a Postdoctoral Fellowship (to C. R. M.) and a fellowship from the Ministerio de Educacion y Ciencia of Spain (to M. H.-M.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Dagger Dagger A Scientist of the Medical Research Council of Canada. To whom correspondence should be addressed: Molecular Oncology Group, Royal Victoria Hospital, 687 Pine Ave. W., Rm. H5.10, Montreal, Quebec H3A 1A1, Canada. Tel.: 514-842-1231 (ext. 5845); Fax: 514-843-1478; E-mail: morag@lan1.molonc.mcgill.ca.

2 M. Holgado-Madruga, D. K. Moscatello, and A. J. Wong, submitted for publication.

    ABBREVIATIONS

The abbreviations used are: HGF, hepatocyte growth factor; MDCK, Madin-Darby canine kidney; PI3K, phosphatidylinositol 3-kinase; PLCgamma 1, phospholipase Cgamma 1; IRS, insulin receptor substrate; PH, pleckstrin homology; BTK, Bruton's tyrosine kinase; DMEM, Dulbecco's modified Eagle's medium; FBS, fetal bovine serum; CSF, colony-stimulating factor; PIP3, inositol 1,4,5-trisphosphate; PIP2, inositol 1,4,5-bisphosphate; GST, glutathione S-transferase; HA, hemagglutinin.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

1. Komada, M., Miyazawa, K., Ishii, T., and Kitamura, N. (1991) Eur. J. Biochem. 204, 857-864[Medline] [Order article via Infotrieve]
2. Ronsin, C., Muscatelli, F., Mattei, M. G., and Breathnach, R. (1993) Oncogene 8, 1195-1202[Medline] [Order article via Infotrieve]
3. Birchmeier, C., and Gherardi, E. (1998) Trends Cell Biol. 10, 404-10
4. Komada, M., and Kitamura, N. (1993) Oncogene 8, 2381-2390[Medline] [Order article via Infotrieve]
5. Weidner, K. M., Sachs, M., and Birchmeier, W. (1993) J. Cell Biol. 121, 145-154[Abstract/Free Full Text]
6. Zhu, H., Naujokas, M. A., and Park, M. (1994) Cell Growth Differ. 5, 359-366[Abstract]
7. Ebens, A., Brose, K., Leonardo, E. D., Hanson, M. G. J., Bladt, F., Birchmeier, C., Barres, B. A., and Tessier-Lavigne, M. (1996) Neuron 17, 1157-1172[CrossRef][Medline] [Order article via Infotrieve]
8. Maina, F., Hilton, M. C., Ponzetto, C., Davies, A. M., and Klein, R. (1997) Genes Dev. 11, 3341-3350[Abstract/Free Full Text]
9. Schmidt, C., Bladt, F., Goedecke, S., Brinkmann, V., Zschiesche, W., Sharpe, M., Gherardi, E., and Birchmeier, C. (1995) Nature 373, 699-702[CrossRef][Medline] [Order article via Infotrieve]
10. Uehara, Y., Minowa, O., Mori, C., Shiota, K., Kuno, J., Noda, T., and Kitamura, N. (1995) Nature 373, 702-705[CrossRef][Medline] [Order article via Infotrieve]
11. Yang, X. M., and Park, M. (1995) Lab. Invest. 73, 483-491[Medline] [Order article via Infotrieve]
12. Kan, M., Zhang, G. H., Zarnegar, R., Michalopoulos, G., Myoken, Y., McKeehan, W. L., and Stevens, J. I. (1991) Biochem. Biophys. Res. Commun. 174, 331-337[CrossRef][Medline] [Order article via Infotrieve]
13. Nakamura, T. (1991) Prog. Growth Factor Res. 3, 67-85[CrossRef][Medline] [Order article via Infotrieve]
14. Zarnegar, R., and Michalopoulos, G. (1989) Cancer Res. 49, 3314-3320[Abstract/Free Full Text]
15. Montesano, R., Schaller, G., and Orci, L. (1991) Cell 66, 697-711[CrossRef][Medline] [Order article via Infotrieve]
16. Soriano, J. V., Pepper, M. S., Nakamura, T., Orci, L., and Montesano, R. (1995) J. Cell Sci. 108, 413-430[Abstract]
17. Zhu, H., Naujokas, M. A., Fixman, E. D., Torossian, K., and Park, M. (1994) J. Biol. Chem. 269, 29943-29948[Abstract/Free Full Text]
18. Faletto, D. L., Kaplan, D. R., Halverson, D. O., Rosen, E. M., and Vande Woude, G. F. (1993) in Hepatocyte Growth Factor:Scatter Factor (Goldberg, I. D. , and Rosen, E. M., eds) , pp. 107-130, Birkhäuser, Basel, Switzerland
19. Fixman, E. D., Fournier, T. M., Kamikura, D. M., Naujokas, M. A., and Park, M. (1996) J. Biol. Chem. 271, 13116-13122[Abstract/Free Full Text]
20. Fixman, E. D., Holgado-Madruga, M., Nguyen, L., Kamikura, D. M., Fournier, T. M., Wong, A. J., and Park, M. (1997) J. Biol. Chem. 272, 20167-20172[Abstract/Free Full Text]
21. Fournier, T. M., Kamikura, D., Teng, K., and Park, M. (1996) J. Biol. Chem. 271, 22211-22217[Abstract/Free Full Text]
22. Ponzetto, C., Bardelli, A., Zhen, Z., Maina, F., dalla Zonca, P., Giordano, S., Graziani, A., Panayotou, G., and Comoglio, P. M. (1994) Cell 77, 261-271[CrossRef][Medline] [Order article via Infotrieve]
23. Nguyen, L., Holgado-Madruga, M., Maroun, C., Fixman, E. D., Kamikura, D., Fournier, T., Charest, A., Tremblay, M. L., Wong, A. J., and Park, M. (1997) J. Biol. Chem. 272, 20811-20819[Abstract/Free Full Text]
24. Maroun, C. R., Holgado-Madruga, M., Royal, I., Naujokas, M. A., Fournier, T. M., Wong, A. J., and Park, M. (1999) Mol. Cell. Biol. 19, 1784-1799[Abstract/Free Full Text]
25. Holgado-Madruga, M., Emlet, D. R., Moscatello, D. K., Godwin, A. K., and Wong, A. J. (1996) Nature 379, 560-564[CrossRef][Medline] [Order article via Infotrieve]
26. Holgado-Madruga, M., Moscatello, D. K., Emlet, D. R., Dieterich, R., and Wong, A. J. (1997) Proc. Natl. Acad. Sci. U. S. A. 94, 12419-12424[Abstract/Free Full Text]
27. Takahashi-Tezuka, M., Yoshida, Y., Fukada, T., Ohtani, T., Tamanaka, Y., Nishida, K., Hibi, M., and Hirano, T. (1998) Mol. Cell. Biol. 18, 4109-4117[Abstract/Free Full Text]
28. Lecoq-Lafon, C., Verdier, F., Fichelson, S., Chretien, S., Gisselbrecht, S., Lacombe, C., and Mayeux, P. (1999) Blood 93, 2578-2585[Abstract/Free Full Text]
29. Carpino, N., Wisniewski, D., Strife, A., Marshak, D., Kobayashi, R., Stillman, B., and Clarkson, B. (1997) Cell 88, 197-204[CrossRef][Medline] [Order article via Infotrieve]
30. Herbst, R., Caroll, P. M., Allard, J. D., Schilling, J., Raabe, T., and Simon, M. A. (1996) Cell 85, 899-909[CrossRef][Medline] [Order article via Infotrieve]
31. Raabe, T., Riesgo-Escovar, J., Liu, X., Bausenwein, B. S., Deak, P., Maroy, P., and Hafen, E. (1996) Cell 85, 911-920[CrossRef][Medline] [Order article via Infotrieve]
32. Yamanashi, Y., and Baltimore, D. (1997) Cell 88, 205-211[CrossRef][Medline] [Order article via Infotrieve]
33. Yenush, L., and White, M. F. (1997) BioEssays 19, 491-500[CrossRef][Medline] [Order article via Infotrieve]
34. Gu, H., Pratt, J. C., Burakoff, S. J., and Neel, B. G. (1998) Mol. Cell 6, 729-740
35. Burks, D. J., Pons, S., Towery, H., Smith-Hall, J., Myers, M. G., Jr., Yenush, L., and White, M. F. (1997) J. Biol. Chem. 272, 27716-27721[Abstract/Free Full Text]
36. Weidner, K. M., Di Cesare, S., Sachs, M., Brinkmann, V., Behrens, J., and Birchmeier, W. (1996) Nature 384, 173-176[CrossRef][Medline] [Order article via Infotrieve]
37. Bardelli, A., Longati, P., Gramaglia, D., Stella, M. C., and Comoglio, P. M. (1997) Oncogene 15, 3103-3111[CrossRef][Medline] [Order article via Infotrieve]
38. Shaw, G. (1996) BioEssays 18, 35-46[CrossRef][Medline] [Order article via Infotrieve]
39. Lemmon, M. A., Ferguson, K. M., and Schlessinger, J. (1996) Cell 85, 621-624[CrossRef][Medline] [Order article via Infotrieve]
40. Lemmon, M. A., Falasca, M., Ferguson, K. M., and Schlessinger, J. (1997) Trends Cell Biol. 7, 237-242
41. Isakoff, S., Cardozo, T., Andreev, J., Li, Z., Ferguson, K. M., Abagyan, R., Lemmon, M. A., Aronheim, A., and Skolnik, E. D. (1999) EMBO J. 18, 5374-5387
42. Rameh, L. E., Arvidsson, A.-K., Carraway III, K. L., Couvillon, A. D., Rathbun, G., Crompton, A., VanRenterghem, B., Czech, M. P., Ravichandran, K. S., Burakoff, S. J., Wang, D. S., Chen, C. S., and Cantley, L. C. (1997) J. Biol. Chem. 272, 22059-22066[Abstract/Free Full Text]
43. Salim, K., Bottomly, M. J., Querfurth, E., Zvelebil, M. J., Gout, I., Scaife, R., Margolis, R. L., Gigg, R., Smith, C. I., Driscoll, P. C., Waterfield, M. D., and Panayotou, G. (1996) EMBO J. 15, 6241-6250[Medline] [Order article via Infotrieve]
44. Fukuda, M., Kojima, T., Kabayama, H., and Mikoshiba, K. (1996) J. Biol. Chem. 271, 30303-30306[Abstract/Free Full Text]
45. Franke, T. F., Kaplan, D. R., Cantley, L. C., and Toker, A. (1997) Science 275, 665-668[Abstract/Free Full Text]
46. Wigler, M., Pellicer, A., Silverstein, S., Axel, R., Urlaub, G., and Chasin, L. (1979) Proc. Natl. Acad. Sci. U. S. A. 76, 1373-1376[Abstract/Free Full Text]
47. Rodrigues, G. A., Naujokas, M. A., and Park, M. (1991) Mol. Cell. Biol. 11, 2962-2970[Abstract/Free Full Text]
48. Frech, M., Andjelkovic, M., Ingley, E., Reddy, K. K., Falck, J. R., and Hemmings, B. A. (1997) J. Biol. Chem. 272, 8474-8481[Abstract/Free Full Text]
49. Garcia, P., Gupta, R., Shah, S., Morris, A. J., Rudge, S. A., Scarlata, S., Petrova, V., McLaughlin, S., and Rebecchi, M. J. (1995) Biochemistry 34, 16228-16234[CrossRef][Medline] [Order article via Infotrieve]
50. Harlan, J. E., Hajduk, P. J., Yoon, H. S., and Fesik, S. W. (1994) Nature 371, 168-170[CrossRef][Medline] [Order article via Infotrieve]
51. Hyvönen, M., Macias, M. J., Nilges, M., Oschkinat, H., Saraste, M., and Wilmanns, M. (1995) EMBO J. 14, 4676-4685[Medline] [Order article via Infotrieve]
52. Konishi, H., Kuroda, S., and Kikkawa, U. (1994) Biochem. Biophys. Res. Commun. 205, 1770-1775[CrossRef][Medline] [Order article via Infotrieve]
53. Kavran, J. M., Klein, D. E., Lee, A., Falasca, M., Isakoff, S. J., Skolnik, E. Y., and Lemmon, M. A. (1998) J. Biol. Chem. 273, 30497-30508[Abstract/Free Full Text]
54. Ferguson, K. M., Lemmon, M. A., Schlessinger, J., and Sigler, P. B. (1995) Cell 83, 1037-1046[CrossRef][Medline] [Order article via Infotrieve]
55. Paterson, H. F., Savopoulos, J. W., Perisic, O., Cheung, R., Ellis, M. V., Williams, R. L., and Katan, M. (1995) Biochem. J. 312, 661-666
56. Yagisawa, H., Sakuma, K., Paterson, H. F., Cheung, R., Allen, V., Hirata, H., Watanabe, Y., Hirata, M., Williams, R. L., and Katan, M. (1998) J. Biol. Chem. 273, 417-424[Abstract/Free Full Text]
57. Cifuentes, M. E., Delaney, T., and Rebecchi, M. J. (1994) J. Biol. Chem. 269, 1945-1994[Abstract/Free Full Text]
58. Wang, D. S., Miller, R., Shaw, R., and Shaw, G. (1996) Biochem. Biophys. Res. Commun. 225, 420-426[CrossRef][Medline] [Order article via Infotrieve]
59. Varnai, P., Rother, K. I., and Balla, T. (1999) J. Biol. Chem. 274, 10983-10989[Abstract/Free Full Text]
60. Nagel, W., Zeitlmann, L., Schilcher, P., Geiger, C., Kolanus, J., and Kolanus, W. (1998) J. Biol. Chem. 273, 14853-14861[Abstract/Free Full Text]
61. Klippel, A., Kavanaugh, W. M., Pot, D., and Williams, L. T. (1997) Mol. Cell. Biol. 17, 338-344[Abstract]
62. James, S. R., Downes, P., Gigg, R., Grove, S. J. A., Holmes, A. B., and Alessi, D. R. (1996) Biochem. J. 315, 709-713
63. Scharenberg, A. M., El-Hillal, O., Fruman, D. A., Beitz, L. O., Li, Z., Lin, S., Gout, I., Cantley, L. C., Rawlings, D. J., and Kinet, J.-P. (1998) EMBO J. 17, 1961-1972[CrossRef][Medline] [Order article via Infotrieve]
64. Vihinen, M., Iwata, T., Kinnon, C., Kwan, S. P., Ochs, H. D., Vorechovsky, I., and Smith, C. I. (1996) Nucleic Acids Res. 24, 160-165[Abstract/Free Full Text]
65. Mattsson, P. T., Vihinen, M., and Smith, C. I. (1996) BioEssays 18, 825-834[CrossRef][Medline] [Order article via Infotrieve]
66. Hyvönen, M., and Saraste, M. (1997) EMBO J. 16, 3396-3404[CrossRef][Medline] [Order article via Infotrieve]
67. Rawlings, D. J., and Witte, O. N. (1995) Semin. Immunol. 7, 237-246[CrossRef][Medline] [Order article via Infotrieve]
68. Rawlings, D. J., Scharenberg, A. M., Park, H., Wahl, M. I., Lin, S., Kato, R. M., Flückiger, A.-C., Witte, O., and Kinet, J.-P. (1996) Science 271, 822-825[Abstract]
69. Stephens, L., Anderson, K., David, S., Erdjument-Bromage, H., Painter, G. F., Holmes, A. B., Gaffney, P. R. J., Reese, C. B., McCormick, F., Tempst, P., Coadwell, J., and Hawkins,